Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kairos Pharma (KAPA) EBITDA Margin (2024 - 2025)

Kairos Pharma (KAPA) has disclosed EBITDA Margin for 2 consecutive years, with 2.91% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA Margin fell 185291.0% year-over-year to 2.91%, compared with a TTM value of 4.58% through Jun 2025, changed N/A, and an annual FY2024 reading of 4.69%, down 408564.0% over the prior year.
  • EBITDA Margin was 2.91% for Q2 2025 at Kairos Pharma, down from 2.53% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1850.0% in Q2 2024 and bottomed at 2.91% in Q2 2025.